Neurocrine Biosciences, Inc. announced an amendment to its agreement with Takeda to develop and commercialize osavampator. Under the updated agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator in all territories worldwide except Japan, where Takeda will reacquire exclusive rights.
Osavampator is a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD). Each company will be responsible for development costs in their respective regions, and both companies are eligible to receive royalty payments.
This streamlined collaboration structure allows Neurocrine to focus on bringing this important medicine to patients as quickly as possible. The company plans to begin the Phase 3 program in the first half of this year, following the successful completion of its End-of-Phase 2 meeting with the FDA for osavampator.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.